TABLE 4.

The class and list of other topical glaucoma monotherapy.

Class	Drug	IOP reduction	Current market status	Usage, dosage	Mechanism	Side effects (ocular)	Side effects (systematic)
α-2 adrenergic agonists	Brimonidine tartrate	20–27%	On the market	Three times daily	Increasing uveoscleral and trabecular outflow; Reducing aqueous humour formation	Blepharitis; Blepharoconjunctivitis; Conjunctivitis; Conjunctival follicles; Mild hyperemia; Staining of the cornea; Blurred vision; Foreign body sensation	—
Carbonic anhydrase inhibitors	Systemic inhibitors: acetazolamide, methazolamide, dichlorophenamide	25–30%	On the market	Twice daily	Reducing aqueous humour formation	—	Numbness and tingling of extremities; Metallic taste; Depression; Fatigue; Malaise; Weight loss; Decreased libido; Gastrointestinal irritation; Metabolic acidosis; Renal calculi; Transient myopia
	Topical inhibitors: Dorzolamide, Brinzolamide	15–25%	On the market	Two or three times daily	Reducing aqueous humour formation	Stinging; Burning or reddening of the eye; Blurred vision; Pruritus; Bitter taste	—
Adenosine receptor agonists	Trabodenoson	—	Discontinued	Twice daily	Increasing trabecular outflow	Eye pain; Conjunctival; Ocular hyperemia; Excoriation	Headache; Back pain; Dermatitis